Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Chinese premier stresses nurturing new drivers for highWill Biden be on the ballot in Ohio and Alabama? That's up to RepublicansTop legislature to review bills on patriotic education, safeguarding national secretsChina's procuratorates, supervisory organs enhance linking mechanism to improve case handlingChinese vice premier stresses preparation for spring farmingXi extends New Year wishes to allCPPCC members interviewed before closing meeting of 2nd session of 14th CPPCC National CommitteeChina's top legislature concludes standing committee sessionTwo Sessions Explainer: Highlights of 2024 Chinese government work reportChina's top legislature concludes standing committee session